Pfenex Inc. To Report Third Quarter 2014 Results And Provide Business Update On Thursday, November 13, 2014
SAN DIEGO, Nov. 6, 2014 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics including high value and difficult to manufacture proteins, announced today that its third quarter 2014 financial results will be released on Thursday, November 13, 2014, after close of market. At 4:30 pm Eastern Time, Pfenex management will host a conference call to discuss the financial results and provide a business update. A press release outlining the financial results and business update will be publicly distributed prior to the call.
Please call 1-877-870-4263 (US) or 1-412-317-0790 (international) and reference Pfenex to access the call. A replay of the conference call will be available approximately one hour after the call until November 21, 2014. To access the teleconference replay please call 1-877-344-7529 (US) or 1-412-317-0088 (international) and enter the passcode 10055734. The conference call will also be available as a webcast. To access the webcast link please log on to www.pfenex.com.
About Pfenex Inc.
Pfenex Inc. is a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics including high-value and difficult to manufacture proteins. The company's lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab), for the potential treatment of patients with retinal diseases. Pfenex has leveraged its Pfenex Expression Technology platform to build a pipeline of product candidates and preclinical products under development including other biosimilars, as well as vaccines, generics and next generation biologics.
Pfenex has used, and intends to continue to use, its Investor Relations website (http://pfenex.investorroom.com), as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit (http://pfenex.investorroom.com).
SOURCE Pfenex Inc.